Weight-loss medications are now used by at least one person in 8.5% of households across Great Britain, placing GLP-1 drugs in more British homes than vegetarians and pescatarians combined, according to research by Worldpanel by Numerator.
Around 2.6 million adults were taking weight-loss drugs in August, representing an increase of roughly 700,000 users since February, when household penetration stood at 6.3%. The rapid expansion follows the UK regulator’s June approval of oral tablet versions such as Wegovy, which went on sale in high-street pharmacies in July, offering an alternative to injections.
Daily Pills and Male Users Fuel Growth
Oral medications now account for more than one in ten (11.2%) of all GLP-1 users. At the same time, male adoption has climbed sharply: men now represent 32% of users, up from 23% in February, with the number of male users nearly doubling over nine months from 440,000 to 830,000.
Nishita Pattni, a senior consultant at Worldpanel by Numerator, noted that user numbers grew almost as much between February and August 2026 as they did during the entire preceding year, adding that the convenience of a daily pill and rising interest among men are likely to broaden the drugs’ appeal even further.
Supermarket Spending Shifts Sharply
The growing uptake of medications such as Wegovy and Mounjaro is also reshaping British grocery shopping, based on a survey of more than 9,600 households:
- Lower Grocery Bills: In the first year after starting the medication, households with a GLP-1 user spent £1bn less on groceries collectively than comparable households—up from £780m estimated in June—equating to 415 million fewer items purchased, or an average reduction of £389 per year per household.
- Decline in Indulgence Items: Spending on alcohol dropped 15% more among GLP-1 households than non-user households, while spending on crisps fell by a similar margin as snacking declined.
- Rise in Portion-Controlled Foods: Sales of frozen ready-meals rose by 30%, alongside higher spending on hot chocolate and malt drinks as users opted for smaller, portion-controlled treats.
GLP-1 medications now appear in roughly the same share of British homes as staples like Kellogg’s Rice Krispies (8.6%) and Corona beer (8.4%). Chantel Kennaugh, head of public sector and nutrition at Worldpanel by Numerator, projected that household usage will exceed 10% in 2027, describing the trend as a structural shift that will force food retailers and manufacturers to rethink their product strategies.
